Brief: Galmed Pharmaceuticals Announces Receipt Of Extension To Meet The Nasdaq's Minimum Bid Price Requirement
Galmed Pharmaceuticals Ltd reports results for the quarter ended in September - Earnings Summary
Galmed Pharmaceuticals Ltd expected to post a loss of 16 cents a share - Earnings Preview
Brief: Galmed Pharmaceuticals Reports Q2 Loss Per Share Of $0.15
Brief: Galmed Reports Significant Anti-Fibrotic Effects Of Aramchol In A Lung Fibrosis Model
Brief: Galmed Pharmaceuticals Announces Receipt Of Nasdaq Minimum Bid Price Notification
U.S. STOCKS ON THE MOVE-Block Inc, Markel Corp, AVROBIO Inc
U.S. STOCKS ON THE MOVE-Boeing Co, Akerna Corp, Workday Inc
U.S. STOCKS ON THE MOVE-Nucor Corp, Stratasys Ltd, Hyatt Hotels Corp
Galmed rises on expansion of development strategy for lead candidate
Brief: Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results
Brief: Galmed Updates Business And Clinical Development Strategy To Better Leverage Aramchol's Anti-Fibrotic Effects
NASDAQ RESUMED AT 02:15 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:10 PM
Galmed Pharmaceuticals Ltd reports results for the quarter ended in December - Earnings Summary
Brief: Galmed Pharmaceuticals Reports Fourth Quarter And Year End 2021 Results
Galmed Pharmaceuticals Ltd expected to post a loss of 30 cents a share - Earnings Preview
Brief: Galmed Reports Interim Results From The Armor Study With Aramchol
Galmed Pharmaceuticals Ltd expected to post a loss of 30 cents a share - Earnings Preview